Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus VALRELEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus VALRELEASE.
GABAPENTIN ENACARBIL vs VALRELEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin enacarbil is a prodrug of gabapentin. It binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulates neuronal excitability and pain transmission.
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Initial: 600 mg orally once daily; titrate to 600 mg three times daily; max 2400 mg/day divided three times daily.
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
None Documented
None Documented
Terminal half-life of gabapentin: 5–7 hours in patients with normal renal function. Renal impairment prolongs half-life proportionally to creatinine clearance decline.
Clinical Note
moderateGabapentin enacarbil + Venlafaxine
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Venlafaxine."
Clinical Note
moderateGabapentin enacarbil + Nefazodone
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone."
Clinical Note
moderateGabapentin enacarbil + Stiripentol
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels.
Renal: 100% as unchanged gabapentin (prodrug is rapidly hydrolyzed to gabapentin after absorption). No biliary or fecal elimination of active drug.
Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
Gabapentin enacarbil + Pomalidomide
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pomalidomide."